Clinical and molecular prognostic factors in newly diagnosed pediatric T-cell lymphoblastic lymphoma: a prospective, multicenter, single-arm phase 2 clinical trial.

The 3-year overall survival (OS) was 78.6% ± 3.3% and event-free survival (event-free survival) was 73.9% ± 3.5%.

Outcomes differed by risk group (P < 0.05), with 3-year OS and event-free survival of 100% and 100% in R1, 82.6% ± 3.4% and 79.5% ± 3.4% in R2, and 58.6% ± 9.1% and 48.3% ± 9.1% in R3.

Progression or recurrence occurred in 42 patients (median: 7 months; 3-year OS: 17.1% ± 6.3%).

Clinical risk factors included R3 assignment and elevated lactate dehydrogenase.